T. Rowe Price Investment Management, Inc. Blueprint Medicines Corp Transaction History
T. Rowe Price Investment Management, Inc.
- $166 Billion
- Q3 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Blueprint Medicines Corp stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 748,692 shares of BPMC stock, worth $70.8 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
748,692
Previous 791,718
5.43%
Holding current value
$70.8 Million
Previous $85.3 Million
18.84%
% of portfolio
0.04%
Previous 0.05%
Shares
9 transactions
Others Institutions Holding BPMC
# of Institutions
350Shares Held
60.3MCall Options Held
2.25MPut Options Held
1.18M-
Vanguard Group Inc Valley Forge, PA6.68MShares$632 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.65MShares$629 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.39MShares$510 Million0.06% of portfolio
-
Wellington Management Group LLP Boston, MA3.96MShares$375 Million0.07% of portfolio
-
State Street Corp Boston, MA2.77MShares$262 Million0.01% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.65B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...